"Lovastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
| Descriptor ID |
D008148
|
| MeSH Number(s) |
D02.455.426.559.847.638.400 D04.615.638.400
|
| Concept/Terms |
Lovastatin- Lovastatin
- Mevinolin
- Monacolin K
- 6-Methylcompactin
- 6 Methylcompactin
|
Below are MeSH descriptors whose meaning is more general than "Lovastatin".
Below are MeSH descriptors whose meaning is more specific than "Lovastatin".
This graph shows the total number of publications written about "Lovastatin" by people in this website by year, and whether "Lovastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1998 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lovastatin" by people in Profiles.
-
Villarreal G, Chatterjee A, Oh SS, Oh DJ, Rhee DJ. Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2014 Mar 19; 55(3):1657-65.
-
Zhao Y, Gartner U, Smith FJ, McLean WH. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol. 2011 May; 131(5):1045-52.
-
Pickering TG. The Food and Drug Administration and over-the-counter statins: an opportunity lost? J Clin Hypertens (Greenwich). 2008 Mar; 10(3):245-8.
-
Milkevitch M, Jeitner TM, Beardsley NJ, Delikatny EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. Biochim Biophys Acta. 2007 Sep; 1771(9):1166-76.
-
Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, Han J, Fineman M, Mitchell M. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007 Feb; 45(2):114-20.
-
Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol. 2005 Nov; 73(11):888-96.
-
Boccuzzi SJ, Weintraub WS, Kosinski AS, Roehm JB, Klein JL. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). Am J Cardiol. 1998 Mar 01; 81(5):632-6.
-
Weintraub WS, Pederson JP. Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study. Am J Cardiol. 1996 Nov 01; 78(9):1036-8.
-
Ballantyne CM, Bourge RC, Domalik LJ, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Radovancevic B, Taylor DO, Ventura HO, Yancy CW, Young JB. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol. 1996 Sep 01; 78(5):532-5.
-
Waksman R, Kosinski AS, Klein L, Boccuzzi SJ, King SB, Ghazzal ZM, Weintraub WS. Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group. Am J Cardiol. 1996 Jul 15; 78(2):221-4.